Article
MPN10 score and survival of molecularly annotated myeloproliferative neoplasm patients.
Leukemia & lymphoma - 1 Apr 2018
ElNahass Yasser H, Mahmoud Hossam K, Mattar Mervat M, Fahmy Omar A, Samra Mohamed A, Abdelfattah Raafat M, ElRefaey Fatma A, Fahmy Hala M, Fathy Gamal M, Abdulgawad Ahmed, AbdelKader Mohamed, Elleithy Hend N, Gamil Mona, Talaat Mohamed, Nader Heba A, ElMetnawy Wafaa H
Abstract excerpt
JAK2, CALR, MPL and triple-negative mutational status has a direct impact on symptom severity and disease burden assessed by MPN10 score in myeloproliferative neoplasms (MPNs). Among 93 patients; median MPN10 score was 48 (5-76) in JAK2 mutants versus 25 (4-80) in JAK2 negative (p < .001); 22.5 (4-65) in CALR mutants versus 35 (5-80) in CALR negative (p < .050) and 21 (10-48) in triple negative versus 40 (4-80)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.